Modulation of PTPRA to treat arthritis
Presented is a method for treating inflammation and autoimmune diseases through the use of a phosphatase rheumatoid arthritis (PT-PRA) antagonist.
1. A method of inhibiting receptor-type tyrosine-protein phosphatase alpha (PTPRA) protein activity in a cell, the method comprising contacting a cell with an effective amount of a PTPRA antagonist thereby inhibiting PTPRA protein activity in said cell, wherein said cell is a fibroblast-like synoviocyte, and wherein said PTPRA antagonist is an anti-PTPRA inhibitory nucleic acid.
2. The method of claim 1 , wherein said anti-PTPRA inhibitory nucleic acid has at least 90% sequence identity to at least 10 contiguous nucleotides of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or a complementary sequence thereof.
3. The method of claim 1 , wherein said anti-PTPRA inhibitory nucleic acid has at least 90% sequence identity to at least 10 contiguous nucleotides of SEQ ID NO: 1, or a complementary sequence thereof.
4. The method of claim 1 , wherein said anti-PTPRA inhibitory nucleic acid has at least 90% sequence identity to at least 10 contiguous nucleotides of SEQ ID NO: 2 or a complementary sequence thereof.
5. The method of claim 1 , wherein said anti-PTPRA inhibitory nucleic acid has at least 90% sequence identity to at least 10 contiguous nucleotides of SEQ ID NO: 3 or a complementary sequence thereof.
6. The method of claim 1 , wherein said anti-PTPRA inhibitory nucleic acid is a morpholino nucleic acid.
7. The method of claim 6 , wherein said morpholino nucleic acid is a single stranded antisense nucleic acid.
8. The method of claim 6 , wherein said morpholino nucleic acid has the sequence of SEQ ID NO:4 or SEQ ID NO:5.
9. The method of claim 6 , wherein said morpholino nucleic acid is a phosphoramidate morpholino nucleic acid.
10. The method of claim 6 , wherein said morpholino nucleic acid is conjugated to a cell permeable moiety.
11. The method of claim 8 , wherein said morpholino nucleic acid has the sequence of SEQ ID NO:4.